Interstrand crosslinking of homologous repair template DNA enhances gene editing in human cells-Reference-Cited by-同舟云学术

Interstrand crosslinking of homologous repair template DNA enhances gene editing in human cells

Published:2023-02-27 Issue:10 Volume:41 Page:1398-1404
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Ghasemi Hannah I.,Bacal Julien,Yoon Amanda C.,Tavasoli Katherine U.,Cruz Carmen,Vu Jonathan T.,Gardner Brooke M.,Richardson Chris D.^ORCID

Abstract

AbstractWe describe a strategy to boost the efficiency of gene editing via homology-directed repair (HDR) by covalently modifying the template DNA with interstrand crosslinks. Crosslinked templates (xHDRTs) increase Cas9-mediated editing efficiencies by up to fivefold in K562, HEK293T, U2OS, iPS and primary T cells. Increased editing from xHDRTs is driven by events on the template molecule and requires ataxia telangiectasia and Rad3-related (ATR) kinase and components of the Fanconi anemia pathway.

Funder

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

https://www.nature.com/articles/s41587-022-01654-y.pdf

Reference35 articles.

1. Nambiar, T. S., Baudrier, L., Billon, P. & Ciccia, A. CRISPR-based genome editing through the lens of DNA repair. Mol. Cell 82, 348–388 (2022).

2. Cornu, T. I., Mussolino, C. & Cathomen, T. Refining strategies to translate genome editing to the clinic. Nat. Med. 23, 415–423 (2017).

3. Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).

4. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012–1019 (2014).

5. Azimi, C. S., Tang, Q., Roybal, K. T. & Bluestone, J. A. NextGen cell-based immunotherapies in cancer and other immune disorders. Curr. Opin. Immunol. 59, 79–87 (2019).